ideology-health
  • Our Solutions
  • About Us
    • ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.

    Dr. Andrew Kuykendall discusses a high-level overview of the LOW-PV trial and the updated NCCN guidelines for low-risk Polycythemia Vera. (Video 1/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Andrew Kuykendall discusses a high-level overview of the LOW-PV trial and the updated NCCN guidelines for low-risk Polycythemia Vera. (Video 1/3)

    Published Jan 2, 2025

    A

    Andrew Kuykendall, M.D.

    Medical Professional

    LOW-PV Trial summary and Updates to NCCN guidelines for Low-risk PV

    Related Videos
    Dr. Amer Zeidan describes the patient management with luspatercept including RS negative and EPO <200 (Video 3/3)

    Dr. Amer Zeidan describes the patient management with luspatercept including RS negative and EPO <200 (Video 3/3)

    Amer Zeidan, MD
    Dr. Himisha Beltran describes the safety of PARP inhibitors in treating BRCA2 mutations in prostate cancer (Video 3/3)

    Dr. Himisha Beltran describes the safety of PARP inhibitors in treating BRCA2 mutations in prostate cancer (Video 3/3)

    Himisha Beltran, MD
    Dr. Martin Dietrich describes the safety of trastuzumab deruxtecan and practical strategies for managing adverse effects (Video 3/3)

    Dr. Martin Dietrich describes the safety of trastuzumab deruxtecan and practical strategies for managing adverse effects (Video 3/3)

    Martin Dietrich
    Dr. Edgardo Santos reviews the impact of SQ amivantamab in EGFRm mNSCLC (Video 2/3)

    Dr. Edgardo Santos reviews the impact of SQ amivantamab in EGFRm mNSCLC (Video 2/3)

    Edgardo Santos, MD
    Dr. Joshua Reuss describes the safety of zongertinib in patients with HER2mutated advanced lung cancer (Video 3/3)

    Dr. Joshua Reuss describes the safety of zongertinib in patients with HER2mutated advanced lung cancer (Video 3/3)

    Joshua Reuss, MD
    Dr. Manali Kamdar reviews the appropriate patient profiles for liso-cel in R/R LBCL (Video 2/3)

    Dr. Manali Kamdar reviews the appropriate patient profiles for liso-cel in R/R LBCL (Video 2/3)

    Manali Kamdar, MD